bannerHON
img
HONnews
HONnews
img PATIENT / PARTICULIER img PROFESSIONNEL DE SANTE img WEBMESTRE img
img
 
img
HONcode sites
Khresmoi - new !
HONselect
News
Conferences
Images

Themes:
A B C D E F G H I
J K L M N O P Q
R S T U V W X Y Z
Browse archive:
2019: A M F J
2018: D N O S A J J M A

 
  Other news for:
Aspirin
Neoplasms
Liver
Liver Diseases
 Resources from HONselect
Does Aspirin Help Prevent Liver Cancer?

By Robert Preidt

FRIDAY, Oct. 5, 2018 (HealthDay News) -- Take two aspirins and reduce your risk of liver cancer? New research suggests this weekly routine might help.

The researchers found that taking two or more standard-dose (325 milligram) pills a week was associated with a 49 percent lower risk of liver cancer.

"Regular use of aspirin led to significantly lower risk of developing [liver cancer], compared to infrequent or no aspirin use. And we also found that the risk declined progressively with increasing aspirin dose and duration of use," said lead study author Dr. Tracey Simon. She's a research fellow in gastroenterology at Massachusetts General Hospital in Boston.

It should be noted, however, that the study did not prove that aspirin reduced liver cause risk, just that there was an association.

For the study, researchers analyzed long-term data from more than 45,800 women and 87,500 men in the United States.

The investigators reported that aspirin's protective effect increased over time. Risk of liver cancer was 59 percent lower among those who took aspirin regularly for five years or more.

The risk reduction declined after people stopped taking aspirin, however. And it disappeared altogether eight years after aspirin was discontinued, the findings showed.

Regular use of acetaminophen (Tylenol) or nonsteroidal anti-inflammatory drugs like ibuprofen (Motrin, Advil) was not linked to reduced risk of liver cancer, according to the study. The results were published Oct. 4 in JAMA Oncology.

The findings support results from previous studies, the researchers said.

However, Simon said additional research is still needed. "Since regular aspirin use carries the risk of increased bleeding, the next step should be to study its impact in populations with established liver disease, since that group is already at risk for primary liver cancer," she said in a hospital news release.

Liver cancer is relatively rare, but it has increased in the United States over the past 40 years. Also, liver cancer death rates have risen faster than those of any other cancer, the researchers noted.

Senior study author Dr. Andrew Chan pointed out that "aspirin use is already recommended for prevention of heart disease and colorectal cancer in certain U.S. adults." Chan is the hospital's chief of clinical and translational epidemiology unit.

"These data also add to a growing list of cancers for which aspirin appears to have anti-cancer activity," he said in the news release.

This could be a rationale for more patients to discuss an aspirin regimen with their doctors, Chan said.

More information

The American Cancer Society has more on liver cancer.

SOURCE: Massachusetts General Hospital, news release, Oct. 4, 2018

Copyright © 2018 HealthDay. All rights reserved. URL:http://consumer.healthday.com/Article.asp?AID=738351

Resources from HONselect: HONselect is the HON's medical search engine. It retrieves scientific articles, images, conferences and web sites on the selected subject.
Neoplasms
Liver
Aspirin
Liver Neoplasms
Risk
Research Personnel
Liver Diseases
Acetaminophen
The list of medical terms above are retrieved automatically from the article.

Disclaimer: The text presented on this page is not a substitute for professional medical advice. It is for your information only and may not represent your true individual medical situation. Do not hesitate to consult your healthcare provider if you have any questions or concerns. Do not use this information to diagnose or treat a health problem or disease without consulting a qualified healthcare professional.
Be advised that HealthDay articles are derived from various sources and may not reflect your own country regulations. The Health On the Net Foundation does not endorse opinions, products, or services that may appear in HealthDay articles.


Home img About us img MediaCorner img HON newsletter img Site map img Ethical policies img Contact